Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
Ching Chan Lin , Te-Chun Hsieh , Tzu-Ting Chen , Ching-Yun Hsieh , Chen-Yuan Lin , Hsin-Hui Huang , Li-Yuan Bai , Po-Han Lin , Chang-Fang Chiu , Su-Peng Yeh , Yu-Min Liao , Woei-Chung Lo
Background: Concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy is the mainstay of treatment for locally advanced nasopharyngeal carcinoma (NPC). However the benefit of adjuvant chemotherapy has been controversial and search for adequate predictive factors is warranted. We conduct this study to evaluate the predictive values of mean standardized uptake value (SUV) measured in [(18)F]-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for adjuvant chemotherapy in patients with locally advanced NPC. Methods: From January 2004 and July 2010, Data collection were performed in 108 NPC patients who underwent (18)F-FDG-PET before CCRT and adjuvant chemotherapy. The SUV was recorded for the primary tumor. All patients received intensity modulated radiotherapy. Concurrent chemotherapy was composed of cisplatin 100mg/m2 triweekly. Adjuvant chemotherapy was consisted of 3 cycles of cisplatin 75 milligrams/m2 and fluorouracil 1000 milligrams/m2for 4 days. Results: The median follow-up was 41months. The optimal cutoff value was 8.35 for SUV. 63.8% of patients had lower SUV (n=69), and 36.2% had higher SUV (n=39). Patients with a lower SUV had a significantly better 3-year overall survival (OS), disease-specific survival (DDS), and distant relapse-free survival (DRFS), but showed no difference in local relapse-free survival. Multivariate analysis showed only stage, SUV and adjuvant chemotherapy were significant in terms of overall survival. In patients with higher SUV, those receiving adjuvant chemotherapy had significantly higher 3-year OS, DDS, and DRFS compared with those without adjuvant chemotherapy. However, in those with lower SUV, there was no difference of OS, DDS and DRFS between patients with and without adjuvant chemotherapy. Conclusions: SUV of (18)F-FDG-PET for primary tumor could identify NPC patients who benefit from adjuvant chemotherapy.
OS(%) | P | DDS(%) | P | DRFS(%) | P | LRFS(%) | P | |
---|---|---|---|---|---|---|---|---|
Lower SUV (with vs without adjuvant chemotherapy) |
95.1 vs 90.7 | 0.534 | 100 vs 95.1 | 0.308 | 95.7 vs 94.1 | 0.887 | 84.5 vs 90.5 | 0.541 |
Higher SUV (with vs without adjuvant chemotherapy) |
88.2 vs 58.9 | 0.026 | 88.2 vs 58.9 | 0.026 | 85.2 vs 50.9 | 0.086 | 88.0 vs 65.5 | 0.098 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Lin-Quan Tang
2024 ASCO Annual Meeting
First Author: Hojung An
2023 ASCO Annual Meeting
First Author: Fang Peng
2022 ASCO Annual Meeting
First Author: He Qianyong